当前位置：首页 > 文献互助 > 互助详情

Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy复制

用户k7g3AjDeE8DM 2天前 29 10 已完结

1. 当前求助状态已完结, 请及时下载应助文件

2. 系统将在 2025-07-16 17:43:28 删除文件

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI: 10.1016/s1470-2045(25)00236-0复制

文献链接: https://linkinghub.elsevier.com/retrieve/pii/S1470204525002360复制

其他信息:

出版社: Elsevier BV
作者: Rachel M Layman; Hyo S Han; Hope S Rugo; Erica M Stringer-Reasor; Jennifer M Specht; E Claire Dees; Peter Kabos; Samuel Suzuki; Sarah C Mutka; Brian F Sullivan; Igor Gorbatchevsky; Robert Wesolowski

上一篇： Toxicity of TAP-144-SR and TAP-144 after repeated administrations and carcinogenicity of TAP-144 in animals

下一篇：On the Mechanical Design of the Rolling Road Addition to the CSUF Wind Tunnel

互助时间线

2025-07-09 18:08:27 [完结求助]

楼主确认了生活猎手应助的文件是正确的, 求助状态变成 已完结

2025-07-09 17:43:28 [上传文件]

生活猎手上传了文件(pdf 44.06 KB), 求助状态变成 待确认

2025-07-09 16:46:17 [发起求助]

最新发布的求助

Discovery of a Novel EGFR PROTAC Degrader against C797S Resistance Mutation with Potent Antitumor Efficacy in NSCLC Treatment 15分钟前
Echolocation over long distances 1小时前
Nitroxide radical contrast agents for safe magnetic resonance imaging: progress, challenges, and perspectives 3小时前
Smart cities for emergency management 3小时前
Oral ENPP1 inhibitor designed using generative Al as next generation STiNG modulator for solid tumors 14小时前
癌患者の痛みに対する塩酸モルヒネ坐剤AN-631の有用性の検討 －硫酸モルヒネ徐放錠との比較― 16小时前
癌患者の疼痛治療におけるAN-631H(塩酸モルヒネ坐剤30mg)の臨床評価 16小时前
Regulatory T cells in the tumour microenvironment 17小时前
POS0734 DAPIROLIZUMAB PEGOL 显示系统性红斑狼疮疾病活动有显着改善：疗效 ... 17小时前
Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial 18小时前
Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer 18小时前
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma 18小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com